Oddo BHF Asset Management Sas Purchases 20,088 Shares of Zoetis Inc. $ZTS

Oddo BHF Asset Management Sas boosted its position in Zoetis Inc. (NYSE:ZTS) by 42.3% during the 1st quarter, HoldingsChannel.com reports. The firm owned 67,557 shares of the company’s stock after purchasing an additional 20,088 shares during the quarter. Oddo BHF Asset Management Sas’ holdings in Zoetis were worth $7,986,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Prosperity Bancshares Inc bought a new position in shares of Zoetis in the fourth quarter worth $25,000. Cassaday & Co Wealth Management LLC bought a new stake in Zoetis during the first quarter valued at $28,000. Lodestone Wealth Management LLC purchased a new position in Zoetis during the fourth quarter worth about $30,000. Root Financial Partners LLC grew its position in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares in the last quarter. Finally, Elyxium Wealth LLC bought a new position in Zoetis in the 4th quarter worth about $32,000. 92.80% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Paul Bisaro acquired 2,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael B. Mccallister bought 3,000 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 11,650 shares of company stock valued at $886,384 in the last ninety days. Company insiders own 0.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ZTS. Citigroup dropped their price target on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. TD Cowen decreased their price objective on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, June 30th. Argus reaffirmed a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Morgan Stanley dropped their target price on shares of Zoetis from $115.00 to $99.00 and set an “overweight” rating for the company in a research report on Wednesday, July 22nd. Finally, HSBC cut their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, July 6th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and a consensus target price of $118.33.

Zoetis Stock Performance

Zoetis stock opened at $77.89 on Thursday. The firm has a fifty day simple moving average of $77.21 and a two-hundred day simple moving average of $103.02. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a twelve month low of $71.47 and a twelve month high of $160.48. The company has a market capitalization of $32.66 billion, a PE ratio of 12.92, a P/E/G ratio of 1.21 and a beta of 0.75.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same period last year, the business posted $1.48 earnings per share. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts expect that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.